Free Trial Information
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...will also support Phase II testing (see "Suppressing Somatostatin" ). CellFe raises $4.8M seed round CellFE Inc....
Read More
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...and 2019. Histogen has raised $38 million to date. First tranche of seed for CellFE CellFE Inc....
Read More
Items per page:
1 - 2 of 2
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

...will also support Phase II testing (see "Suppressing Somatostatin" ). CellFe raises $4.8M seed round CellFE Inc....
Read More
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...and 2019. Histogen has raised $38 million to date. First tranche of seed for CellFE CellFE Inc....
Read More
Items per page:
1 - 2 of 2